Karen Fernandez, MD
Ophthalmology · Charleston, SCNPI 1205132800
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Glaukos Corporation accounts for 65.7% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $9,240, more than ten times the $344 reported in 2019. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $221.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$9K
- Dompe US, Inc.$1K
- Alcon$739
- Johnson & Johnson Surgical Vision, Inc.$607
- Bausch & Lomb Americas Inc.$326
- Bausch & Lomb, A Division Of Bausch Health US, LLC$226
- plus $1K from 13 others
Across 1 payment — averaging $8500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$9K
What the payments were for
- Consulting fees$6,14347%
- Speaking & faculty fees$1,0008%
- Travel & lodging$1,87214%
- Food & beverage$4,04631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 6 | $8,575 |
| Dompe US, Inc. | 4 | $1,134 |
| Alcon | 10 | $739 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $607 |
| Bausch & Lomb Americas Inc. | 8 | $326 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $226 |
| Biotissue Holdings Inc. | 1 | $206 |
| Oyster Point Pharma, Inc. | 2 | $189 |
| AbbVie(2 entities) | 3 | $176 |
| Abbott | 1 | $137 |
| Omeros Corporation | 1 | $120 |
| Tarsus Pharmaceuticals, Inc. | 4 | $118 |
| Regeneron Healthcare Solutions, Inc. | 1 | $114 |
| Harrow Eye, LLC | 2 | $111 |
| Alcon Research LLC | 3 | $105 |
| Sun Pharmaceutical Industries Inc. | 1 | $102 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Novartis | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epioxa$6,143
- Travoprost Intraocular Implant - iDose$2,142
- Oxervate$1,106
- Clareon$259
- enVista MX60 IOL$254
- Tecnis IOL$219
- Photrexa Viscous and Photrexa$185
- AcrySof$147
- AMPLATZER TALISMAN$137
- STELLARIS$134
- ARGOS$129
- Tecnis Simplicity$121
- OMIDRIA$120
- EYLEA HD$114
- RESTASIS MULTIDOSE$108
- CATALYS SYSTEM$105
- CEQUA$102
How this compares
$13,061 in reported general payments places this provider in the 90th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 166 | $145,279 |
| CystadropsCysteamine Hcl | 13 | $116,257 |
| RestasisCyclosporine | 92 | $77,682 |
| MieboPerfluorohexyloctane/Pf | 77 | $56,488 |
| Cyclosporine | 115 | $43,627 |
| Restasis MultidoseCyclosporine | 67 | $43,446 |
| TyrvayaVarenicline Tartrate | 20 | $14,012 |
| Prednisolone Acetate | 136 | $6,336 |
| Doxycycline Ir-DrDoxycycline Monohydrate | 11 | $5,609 |
| Loteprednol Etabonate | 23 | $3,342 |
| Brimonidine Tartrate | 11 | $2,117 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 17 | $1,790 |
| ValacyclovirValacyclovir Hcl | 34 | $1,724 |
| ErythromycinErythromycin Base | 74 | $934 |
| MoxifloxacinMoxifloxacin Hcl | 38 | $914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $326 | $201,766243 claims |
| AbbVieRestasis, Restasis Multidose | $176 | $121,128159 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $189 | $14,01220 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $226 | $3,34223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Charleston
- Karolinne RochaCharleston$552K
- Drew DicksonCharleston$53K
- Mona CamacciCharleston$26K
- Cole MillikenCharleston$17K
- Daniel AlfaroCharleston$15K
- John KerrisonCharleston$12K
- Eric JablonCharleston$12K
- Marion WilsonCharleston$9K
- Michael JohnsonCharleston$9K
- Berdine BurgerCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.